Bio-Techne announced that Asuragen, part of Bio-Techne’s Molecular Diagnostics Division, has completed the Class C Certification under the new European Union In Vitro Diagnostic Regulation for its QuantideX qPCR BCR-ABL IS Kit. Previously, the kit was CE-IVD marked for sale in the EU in compliance with the In Vitro Diagnostic Directive, which has now been replaced by the IVDR. The QuantideX qPCR BCR-ABL IS Kit gives labs a robust and reliable tool for monitoring chronic myeloid leukemia patients.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH:
- Alibaba downgraded, Disney upgraded: Wall Street’s top analyst calls
- Bio-Techne initiated with an Outperform at Scotiabank on market-leading growth
- Bio-Techne initiated with an Outperform at Scotiabank
- Macy’s upgraded, New York Community downgraded: Wall Street’s top analyst calls
- Bio-Techne price target lowered to $85 from $88 at Deutsche Bank